CDK4 and neuroblastoma: CDK4 has been associated with poor prognosis and decreased survival in established tumors, including NB and its inhibition or degradation leads to G0/G1 phase arrest.20,21 The current strategies targeting CDK4 mainly focus on elimination of CDK4 catalytic activity via several potential CDK4 inhibitors.